LCC
IDXG

Lincoln Capital Corp’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

Lincoln Capital Corp’s Portfolio IDXG Stock Details IDXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,035
Closed -$9K – 57
2018
Q1 		$9K Buy
1,035
+35
+4% +$360 0.01% 51
2017
Q4 		$10K Buy
+1,000
New +$12.1K 0.01% 50

Other funds holding IDXG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
WealthSource Partners San Luis Obispo, California $1.54B AUM 16.68% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $43.3B AUM 29.3% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Lincoln Capital Corp's IDXG Position: Q2 2018 in Review

Lincoln Capital Corp sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q2 2018, closing a stake of 1,035 shares — an estimated $9K sold.

Lincoln Capital Corp first reported a position in IDXG in Q4 2017 and held it in 2 quarters. The position peaked at $10K in Q4 2017. 17 funds tracked by Wall St. Rank hold IDXG as of Q2 2018.

  • Lincoln Capital Corp reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • Lincoln Capital Corp sold 1,035 Interpace Biosciences, Inc. Common Stock shares in Q2 2018, an estimated $9K.
  • Lincoln Capital Corp first reported a position in Interpace Biosciences, Inc. Common Stock in Q4 2017 and held it in 2 quarters.
  • Lincoln Capital Corp's Interpace Biosciences, Inc. Common Stock position peaked at $10K in Q4 2017.
  • 17 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q2 2018.

Based on Lincoln Capital Corp's 13F filing for Q2 2018, filed 26 Jul 2018.